X0202 SCHEDULE 13G/A 0000902664-25-002357 0001784547 XXXXXXXX LIVE 4 Voting Common Stock, par value $0.0001 per share 03/31/2026 0001799448 Aligos Therapeutics, Inc. 01626L204 ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 Rule 13d-1(b) Woodline Partners LP DE 239362.00 0.00 239362.00 0.00 239362.00 N 4.4 PN IN Includes 62,000 shares of Voting Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants. Aligos Therapeutics, Inc. One Corporate Drive, 2nd Flood, South San Francisco, CA 94080 This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of voting common stock, par value $0.0001 per share ("Voting Common Stock"), and shares of Voting Common Stock issuable upon exercise of warrants of Aligos Therapeutics, Inc. (the "Company") directly held by the Woodline Fund. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Voting Common Stock reported herein. The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111. Woodline Partners is a Delaware limited partnership. N IA The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 5,387,807 shares of Voting Common Stock outstanding as of March 2, 2026, as reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 5, 2026, and assumes the exercise of the warrants reported herein. 4.4% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. N Y N See Item 2(a). Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Woodline Partners LP /s/ Erin Mullen 05/15/2026